Business news

Glenmark Pharma despite market scope Q1 results range

Glenmark Pharma Stock Price News: Shares of Glenmark Pharmaceuticals, Mumbai-based stock, faced sales pressure on Monday, and the Nifty50’s gains fell by 1% amid hopes of cutting GST’s tax rates. The drug maker’s shares fell 4.6% to Rs 1,949 on BSE. At 3 pm, the stock traded with the symbol Glenmark of the BSE and NSE exchanges – down 3.4% at Rs 1,974.3 and 3.5% respectively, and was 1,974 rupees in BSE and NSE respectively.

Meanwhile, the title index Nifty 50 and Sensex have gathered 1% each year after the central government announced a new GST reform, which will be implemented by Diwali this year.

Also read: PM’s GST reform: How the Centre covers revenue loss of Rs 6 billion

Glenmark Pharma Q1 FY26 Results | Top and Bottom Lines and Expectations

After Thursday’s market hours, Glenmark Pharma reported consolidated net profit of Rs 468 crore for the April-June period, due to a special loss of Rs 3.22 crore, down 86.2% from the corresponding period a year ago.

According to regulatory documents, its revenue in the first quarter increased by 0.6% to 326.44 billion.

According to Zee Business Research, the pharmaceutical company is expected to have a net profit of Rs 3.75 crore and revenue of Rs 3,513 crore, and is currently the first QURATER of the financial year.

Glenmark Pharma Q1 Revenue | How drug manufacturers in Mumbai perform well in operations

The drug manufacturer’s June quarterly earnings before interest, taxes, depreciation and amortization were Rs 5,805 crore, down 1.3% year-on-year.

According to the document, its profit margin – a key measure of profitability – signed under filings at 30 basis points (bps) to 17.8%.

According to the study, the Mumbai-based company is estimated to register a quarterly EBITDA of Rs 651 crore.

Analysts fixed their quarterly margin at 19%.

Glenmark Pharma Sharing vs Nifty 50 vs Nifty Pharma

At current levels, Glenmark stock has risen 22.3% so far in 2025, with a significant increase of more than 4.9% in the Nifty 50 and a 5.7% decline in Nifty Pharma.

Also Read: HSBC Reports Reducing GST may increase automatic demand, creating jobs in India.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button